IMRX Quote, Financials, Valuation and Earnings

AN2 Therapeutics has a net margin of -- compared to Immuneering's net margin of --. Immuneering's return on equity of -- beat AN2 Therapeutics's return on equity of --.

Immuneering has a consensus price target of --, signalling upside risk potential of 432.9%. On the other hand AN2 Therapeutics has an analysts' consensus of -- which suggests that it could grow by 85.19%. Given that Immuneering has higher upside potential than AN2 Therapeutics, analysts believe Immuneering is more attractive than AN2 Therapeutics.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AN2 Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AN2 Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. AN2 Therapeutics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than AN2 Therapeutics quarterly revenues of --. Immuneering's net income of -$14.6M is lower than AN2 Therapeutics's net income of -$12.7M. Notably, Immuneering's price-to-earnings ratio is -- while AN2 Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 217.13x versus -- for AN2 Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -- compared to Immuneering's net margin of -4.76%. Immuneering's return on equity of -- beat Amicus Therapeutics's return on equity of -71.17%.

Immuneering has a consensus price target of --, signalling upside risk potential of 432.9%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 79.99%. Given that Immuneering has higher upside potential than Amicus Therapeutics, analysts believe Immuneering is more attractive than Amicus Therapeutics.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Immuneering's net income of -$14.6M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Immuneering's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 217.13x versus 5.91x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Immuneering's net margin of -49.65%. Immuneering's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Immuneering has a consensus price target of --, signalling upside risk potential of 432.9%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than Immuneering, analysts believe NovaBay Pharmaceuticals is more attractive than Immuneering.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Immuneering's net income of -$14.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Immuneering's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 217.13x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Immuneering's net margin of -54.2%. Immuneering's return on equity of -- beat PTC Therapeutics's return on equity of --.

Immuneering has a consensus price target of --, signalling upside risk potential of 432.9%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 29.81%. Given that Immuneering has higher upside potential than PTC Therapeutics, analysts believe Immuneering is more attractive than PTC Therapeutics.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Immuneering's net income of -$14.6M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Immuneering's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 217.13x versus 3.84x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.